Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis

Published:September 11, 2015DOI:https://doi.org/10.1016/j.thromres.2015.09.013

      Highlights

      • Prasugrel inhibited ADP-induced platelet aggregation in non-human primates.
      • Prasugrel reduced ischaemic infarct volume in a thrombotic stroke model.
      • Prasugrel also ameliorated neurological deficits in the same model.
      • This non-human primate model of thrombotic stroke is useful for stroke research.

      Abstract

      Several clinical trials have demonstrated the benefits of thienopyridine monotherapy in ischaemic stroke patients. Non-human primate models of ischaemic stroke have been used for various antithrombotic agents; however, to the best of our knowledge, there is no data on the effects of P2Y12 antagonists in models, such as the thrombotic middle cerebral artery occlusion (MCAO) monkey model. Accordingly, it remains unclear what level of inhibition of platelet aggregation (IPA) is required for optimal treatment of ischaemic stroke. In the present study, we investigated the effects of prasugrel, a third-generation thienopyridine antiplatelet drug, on platelet aggregation, thrombus formation and cerebral infarct volume in a non-human primate model. Daily oral administration of prasugrel resulted in significant and stable platelet inhibitory effects on Day 3, with IPA values ranging from 31% to 36% at 0.3 mg/kg/day and from 44% to 50% at 1 mg/kg/day. These IPA levels encompassed values observed in clinical trials of clopidogrel, and were thus selected for further study. In the thrombotic MCAO model, prasugrel increased MCA patency in a dose-dependent manner and significantly reduced ischaemic infarct volume by approximately 70% at 0.3 mg/kg/day and 90% at 1 mg/kg/day without increasing haemorrhagic infarction. Prasugrel also significantly reduced neurological deficit scores by 60% at 0.3 mg/kg/day and 80% at 1 mg/kg/day. In conclusion, prasugrel treatment resulted in effective reduction of ischaemic infarction and an associated improvement in neurological function without increasing haemorrhagic infarction. These data suggest that prasugrel monotherapy would be effective for the prevention of thrombotic stroke.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • Adams R.J.
        • Berry J.D.
        • Brown T.M.
        • et al.
        Heart disease and stroke statistics—2011 update: a report from the American Heart Association.
        Circulation. 2011; 123: e18-209
        • Nagai N.
        • Zhao B.Q.
        • Suzuki Y.
        • Ihara H.
        • Urano T.
        • Umemura K.
        Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice.
        J. Cereb. Blood Flow Metab. 2002; 22: 648-651
        • Maeda M.
        • Furuichi Y.
        • Noto T.
        • Matsuoka N.
        • Mutoh S.
        • Yoneda Y.
        Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model.
        Brain Res. 2009; 1254: 99-108
        • Moriguchi A.
        • Maeda M.
        • Mihara K.
        • Aoki T.
        • Matsuoka N.
        • Mutoh S.
        FK419, a novel non peptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
        J. Cereb. Blood Flow Metab. 2005; 25: 75-86
        • Zhao B.Q.
        • Suzuki Y.
        • Kondo K.
        • Kawano K.
        • Ikeda Y.
        • Umemura K.
        A novel MCA occlusion model of photothrombotic ischemia with cyclic flow reductions: development of cerebral hemorrhage induced by heparin.
        Brain Res. Protocol. 2002; 9: 85-92
        • Ikeda S.
        • Harada K.
        • Ohwatashi A.
        • Kamikawa Y.
        • Yoshida A.
        A new non-human primate model of photochemically induced cerebral infarction.
        PLoS ONE. 2013; 8e60037
        • Sawada H.
        • Nishimura N.
        • Suzuki E.
        • Zhuang J.
        • Hasegawa K.
        • Takamatsu H.
        • et al.
        SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates.
        J. Cereb. Blood Flow Metab. 2014; 34: 235-241
        • Kaku S.
        • Umemura K.
        • Mizuno A.
        • Yano S.
        • Suzuki K.
        • Kawasaki T.
        • et al.
        Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
        Eur. J. Pharmacol. 1998; 345: 185-192
        • Maeda M.
        • Moriguchi A.
        • Mihara K.
        • Aoki T.
        • Takamatsu H.
        • Matsuoka N.
        • et al.
        FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
        J. Cereb. Blood Flow Metab. 2005; 25: 108-118
        • Furuichi Y.
        • Maeda M.
        • Matsuoka N.
        • Mutoh S.
        • Yanagihara T.
        Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator.
        Exp. Neurol. 2007; 204: 138-146
        • Gent M.
        • Blakely J.A.
        • Easton J.D.
        • Ellis D.J.
        • Hachinski V.C.
        • Harbison J.W.
        • et al.
        The Canadian American ticlopidine study (CATS) in thromboembolic stroke.
        Lancet. 1989; 1: 1215-1220
        • Steering Committee C.A.P.R.I.E.
        A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Fukuuchi Y.
        • Tohgi H.
        • Okudera T.
        • Ikeda Y.
        • Miyanaga Y.
        • Uchiyama S.
        • et al.
        A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction.
        Cerebrovasc. Dis. 2008; 25: 40-49
        • Sacco R.L.
        • Diener H.C.
        • Yusuf S.
        • Cotton D.
        • Ounpuu S.
        • Lawton W.A.
        • et al.
        Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
        N. Engl. J. Med. 2008; 359: 1238-1251
        • Caplain H.
        • Cariou R.
        Long-term activity of clopidogrel: a three-month appraisal in healthy volunteers.
        Semin. Thromb. Hemost. 1999; 25: S21-S24
        • Thebault J.J.
        • Kieffer G.
        • Lowe G.D.
        • Nimmo W.S.
        • Cariou R.
        Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
        Semin. Thromb. Hemost. 1999; 25: S9-14
        • Rao T.R.
        • Usha P.R.
        • Naidu M.U.
        • Gogtay J.A.
        • Meena M.
        Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures.
        Curr. Ther. Res. Clin. Exp. 2003; 64: 685-696
        • Jakubowski J.A.
        • Matsushima N.
        • Asai F.
        • Naganuma H.
        • Brandt J.T.
        • Hirota T.
        • et al.
        A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
        Br. J. Clin. Pharmacol. 2007; 63: 421-430
        • Serebruany V.L.
        • Steinhubl S.R.
        • Berger P.B.
        • Malinin A.I.
        • Bhatt D.L.
        • Topol E.J.
        Variability in platelet responsiveness to clopidogrel among 544 individuals.
        J. Am. Coll. Cardiol. 2005; 45: 246-251
        • Goh C.
        • Churilov L.
        • Mitchell P.
        • Dowling R.
        • Yan B.
        Clopidogrel hyper-response and bleeding risk in neurointerventional procedures.
        AJNR Am. J. Neuroradiol. 2013; 34: 721-726
        • Niitsu Y.
        • Jakubowski J.A.
        • Sugidachi A.
        • Asai F.
        Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
        Semin. Thromb. Hemost. 2005; 31: 184-194
        • Jakubowski J.A.
        • Winters K.J.
        • Naganuma H.
        • Wallentin L.
        Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
        Cardiovasc. Drug. Rev. 2007; 25: 357-374
        • Dobesh P.P.
        Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
        Pharmacotherapy. 2009; 29: 1089-1102
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • Montalescot G.
        • Ruzyllo W.
        • Gottlieb S.
        • et al.
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N. Engl. J. Med. 2007; 357: 2001-2015
        • Michelson A.D.
        • Frelinger 3rd, A.L.
        • Braunwald E.
        • Downey W.E.
        • Angiolillo D.J.
        • Xenopoulos N.P.
        • et al.
        Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
        Eur. Heart J. 2009; 30: 1753-1763
        • Kimura T.
        • Isshiki T.
        • Ogawa H.
        • Yokoi H.
        • Yamaguchi T.
        • Ikeda Y.
        Randomized, double-blind, dose-finding, phase II study of prasugrel in Japanese patients undergoing elective percutaneous coronary intervention.
        J. Atheroscler. Thromb. 2015; 22: 557-569
        • Saito S.
        • Isshiki T.
        • Kimura T.
        • Ogawa H.
        • Yokoi H.
        • Nanto S.
        • et al.
        Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
        Circ. J. 2014; 78: 1684-1692
        • Isshiki T.
        • Kimura T.
        • Ogawa H.
        • Yokoi H.
        • Nanto S.
        • Takayama M.
        • et al.
        Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention: phase III, randomized, double-blind study.
        Circ. J. 2014; 78: 2926-2934
        • Tomizawa A.
        • Ohno K.
        • Jakubowski J.A.
        • Mizuno M.
        • Sugidachi A.
        Comparison of antiplatelet effects of prasugrel and ticagrelor on cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
        Thromb. Haemost. 2013; 110: 769-776
        • Maeda M.
        • Takamatsu H.
        • Furuichi Y.
        • Noda A.
        • Awaga Y.
        • Tatsumi M.
        • et al.
        Characterization of a novel thrombotic middle cerebral artery occlusion model in monkeys that exhibits progressive hypoperfusion and robust cortical infarction.
        J. Neurosci. Methods. 2005; 146: 106-115
        • Kito G.
        • Nishimura A.
        • Susumu T.
        • Nagata R.
        • Kuge Y.
        • Yokota C.
        • et al.
        Experimental thromboembolic stroke in cynomolgus monkey.
        J. Neurosci. Methods. 2001; 105: 45-53
        • Brandt J.T.
        • Close S.L.
        • Iturria S.J.
        • Payne C.D.
        • Farid N.A.
        • Ernest 2nd, C.S.
        • et al.
        Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
        J. Thromb. Haemost. 2007; 5: 2429-2436
        • Mega J.L.
        • Close S.L.
        • Wiviott S.D.
        • Shen L.
        • Hockett R.D.
        • Brandt J.T.
        • et al.
        Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
        Circulation. 2009; 119: 2553-2560
        • Wiviott S.D.
        • Desai N.
        • Murphy S.A.
        • Musumeci G.
        • Ragosta M.
        • Antman E.M.
        • et al.
        Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
        Am. J. Cardiol. 2011; 108: 905-911